JP2015504071A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504071A5
JP2015504071A5 JP2014551304A JP2014551304A JP2015504071A5 JP 2015504071 A5 JP2015504071 A5 JP 2015504071A5 JP 2014551304 A JP2014551304 A JP 2014551304A JP 2014551304 A JP2014551304 A JP 2014551304A JP 2015504071 A5 JP2015504071 A5 JP 2015504071A5
Authority
JP
Japan
Prior art keywords
seq
composition
group
cell
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014551304A
Other languages
English (en)
Japanese (ja)
Other versions
JP6523685B2 (ja
JP2015504071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/020058 external-priority patent/WO2013103658A1/en
Publication of JP2015504071A publication Critical patent/JP2015504071A/ja
Publication of JP2015504071A5 publication Critical patent/JP2015504071A5/ja
Application granted granted Critical
Publication of JP6523685B2 publication Critical patent/JP6523685B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014551304A 2012-01-03 2013-01-03 Muc1腫瘍抗原のネイティブ及びアゴニストctlエピトープ Active JP6523685B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261582723P 2012-01-03 2012-01-03
US61/582,723 2012-01-03
PCT/US2013/020058 WO2013103658A1 (en) 2012-01-03 2013-01-03 Native and agonist ctl epitopes of the muc1 tumor antigen

Publications (3)

Publication Number Publication Date
JP2015504071A JP2015504071A (ja) 2015-02-05
JP2015504071A5 true JP2015504071A5 (https=) 2016-02-25
JP6523685B2 JP6523685B2 (ja) 2019-06-05

Family

ID=47559756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551304A Active JP6523685B2 (ja) 2012-01-03 2013-01-03 Muc1腫瘍抗原のネイティブ及びアゴニストctlエピトープ

Country Status (8)

Country Link
US (1) US10138271B2 (https=)
EP (1) EP2800762B1 (https=)
JP (1) JP6523685B2 (https=)
AU (1) AU2013206896B2 (https=)
CA (1) CA2860599C (https=)
DK (1) DK2800762T3 (https=)
ES (1) ES2664325T3 (https=)
WO (1) WO2013103658A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
AU2008219065B2 (en) 2007-02-19 2014-01-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
WO2015061416A2 (en) 2013-10-23 2015-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
US11298413B2 (en) 2015-09-16 2022-04-12 Io Biotech Aps Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
CN110198733B (zh) * 2016-09-28 2024-04-30 巴法里安诺迪克有限公司 用于增强痘病毒中转基因的稳定性的组合物和方法
EP3542814B1 (en) 2018-03-21 2022-08-24 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Novel peptide-based compounds for use in the prevention, treatment and/or detection of cancer
JP7555334B2 (ja) 2018-10-05 2024-09-24 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えmva、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
CA3119503A1 (en) 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
US20230190922A1 (en) 2019-11-20 2023-06-22 Bavarian Nordic A/S Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
US20250101127A1 (en) * 2022-01-24 2025-03-27 Cyron Therapeutics Co., Ltd. Antibody specifically binding to muc-1 and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
IE912535A1 (en) 1990-07-27 1992-01-29 Res Dev Foundation Liposomes that Provide Thymic Dependent Help to Weak Vaccine¹Antigens
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
CA2289742C (en) 1997-05-08 2013-07-16 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
US20090004212A1 (en) * 1997-12-30 2009-01-01 Franz-Georg Hanisch Tumour vaccines for MUC1-positive carcinomas
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2383737C (en) * 1999-09-08 2011-01-18 Transgene S.A. Muc-1 derived peptides
EP2363493B1 (en) 2003-02-20 2012-11-14 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
WO2005046622A2 (en) 2003-11-12 2005-05-26 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
DK1694364T3 (da) 2003-11-12 2014-07-21 Us Government System til behandling og forebyggelse af brystcancer
EP1697399B1 (en) * 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
US20090317414A1 (en) * 2006-07-25 2009-12-24 4G Vaccines Pty Ltd Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
SG10201607663YA (en) 2011-08-17 2016-11-29 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2015504071A5 (https=)
CN103751771B (zh) 免疫诱导剂
KR102874251B1 (ko) 신생항원 및 이의 용도
TWI869347B (zh) 新抗原及其用途
JP6558699B2 (ja) 抗原提示を促進するエピトープ間配列を含むt細胞誘導ワクチン
CN1805758B (zh) 核酸和细胞疫苗的组分
RU2008114624A (ru) Композиции и способы для лечения опухолей, презентирующих антигены сурвивина
CN106029699A (zh) Wt1抗原性多肽和含有该多肽的抗肿瘤剂
US20230190899A1 (en) Immune inducer
KR20220110181A (ko) 다중-도메인 단백질 백신
US20220331417A1 (en) Modified vesicular stomatitis virus glycoprotein and uses thereof for the treatment of brain tumors
JP2012504948A (ja) ヒト上皮細胞の免疫賦活活性の増強剤としてのオンコスタチンm
JP3876162B2 (ja) 肝細胞癌の治療のための方法及び組成物
EP1074267B1 (en) Induction of antigen-specific T cells by interferon
CN108697757B (zh) 免疫诱导剂
RU2733841C2 (ru) Иммуноиндуцирующее средство
JP7160462B2 (ja) 免疫誘導剤
CA2993427C (en) Immune inducer
BR112018001542B1 (pt) Iindutor de imunidade e uso do indutor de imunidade